Today: 15 June 2026
Browse Category

NASDAQ:BNTX 22 June 2025 - 13 June 2026

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol Myers Squibb priced €5 billion in senior notes across five tranches, with closing expected Nov. 10; proceeds will fund a debt tender offer running through Dec. 3. The company agreed to a $239 million settlement in a Celgene class action, pending court approval. BioNTech raised its 2025 revenue outlook after receiving payments from a new BMS alliance. FDA approved a generic for Sprycel on Nov. 7.
9 November 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
22 June 2025
···········

Stock Market Today

  • Brazil Weather Concerns Push Coffee Prices Higher Amid Supply Risks
    June 15, 2026, 1:48 PM EDT. Coffee prices rose sharply with July arabica up 2.06% and robusta up 0.5%, hitting multi-week highs due to persistent rain in Brazil delaying harvests. Brazil's coffee-growing regions face continued rainfall, pressuring supply. ICE inventories for arabica and robusta declined to multi-month lows, supporting prices. Additionally, a potential Super El Niño weather event threatens 2026/27 crops, with NOAA estimating a 67% chance. Despite forecasts for record Brazilian production, weather risks and disruptions, including the Strait of Hormuz closure raising shipping costs, bolster market concerns. Meanwhile, robusta prices face bearish pressure from rising Vietnamese exports driving global supply growth.

Latest articles

Pattern Group Slides as Knox Lane Affiliate Plans 8 Million Share Sale

Pattern Group Slides as Knox Lane Affiliate Plans 8 Million Share Sale

15 June 2026
Pattern Group shares plunged 11% to $18.61 after a Knox Lane-affiliated pre-IPO holder launched a secondary offering of 8 million Series A shares, with an option for 1.2 million more; Pattern will not receive proceeds, and the increased share supply weighed on investor sentiment.
Nasdaq Tech Stocks Climb, QQQ Gains After U.S.-Iran Deal Hopes

Nasdaq Tech Stocks Climb, QQQ Gains After U.S.-Iran Deal Hopes

15 June 2026
Invesco QQQ Trust surged 3.1% to $743.54 as a preliminary U.S.-Iran deal sent oil prices down 5%, easing inflation and rate-hike fears, and fueling a tech-led rally with chip stocks like Micron up 9.2% and Nvidia up 3%, while leveraged fund TQQQ soared 9.2%.
Accenture drops on Morgan Stanley downgrade tied to AI spending

Accenture drops on Morgan Stanley downgrade tied to AI spending

15 June 2026
Morgan Stanley downgraded Accenture to Equal Weight and slashed its price target to $177 from $240, citing weaker-than-expected IT services budget growth and AI spending pressure; Accenture shares recently traded near $169, down about 0.8%, after falling 43.9% over the past year as investors await clarity on AI-driven demand ahead of the June 18 earnings call.
Go toTop